BioXcel Therapeutics, Inc. (BTAIQ)
BTAIQ is quoted over the counter, not listed on an exchange. BioXcel Therapeutics, Inc. files reports with the SEC; the numbers below come from SEC filings and from daily closes, each with its source.
Closes: Yahoo Finance daily closes, last bar 2026-11-16.
Profile
| Field | Value |
|---|---|
| Ticker | BTAIQ, quoted over the counter |
| SEC CIK | 0001720893 |
| OTC Markets tier | Pink (price source, 2026-11-13) |
| SEC industry code | Pharmaceutical Preparations |
| Business address | New Haven, CT |
| Incorporated in | DE |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "We have identified conditions and events that raise substantial doubt about our ability to continue as a going concern." | 10-Q 2026-08-13 |
| Cash and burn | $12.8M cash; operating cash flow -$12.7M a quarter. | Report 2026-06-30 |
| Shares outstanding | 31,305,499 (2026-08-11); 14,556,743 a year earlier; 29,267,197 three years earlier. 3y figure adjusted for split (1-for-16 overall). | Cover page 2026-08-11 |
| Reverse splits, 3 years | 1; latest 1-for-16 on 2025-02-10 | Source 2025-02-10 |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the market | Latest 2026-03-11 |
| Exchange deficiency notices, 12 months | 1 (8-K item 3.01) | 8-K 2026-09-01 |
| Auditor | Ernst & Young LLP, Stamford, Connecticut, United States | PCAOB Form AP 2026-04-09 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $36K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | $182K | -$14.7M | -$6.1M | $12.8M | $104.5M | $742K | 10-Q 2026-08-13 |
| Q1 2026 2026-03-31 | $206K | -$12.7M | -$11.8M | $17.2M | $100.3M | $680K | 10-Q 2026-05-15 |
| Q4 2025 2025-12-31 | $256K | -$12.5M | -$14.2M | $28.4M | $109.6M | $642K | 10-K 2026-03-27 |
| Q3 2025 2025-09-30 | $98K | -$30.9M | -$18.8M | $36.2M | $109.1M | $752K | 10-Q 2025-11-12 |
| Q2 2025 2025-06-30 | $120K | -$19.2M | -$12.6M | $17.4M | $108.7M | $868K | 10-Q 2026-08-13 |
| Q1 2025 2025-03-31 | $168K | -$7.3M | -$12.0M | $31.0M | $105.5M | $1.9M | 10-Q 2026-05-15 |
| Q4 2024 2024-12-31 | $366K | -$10.9M | -$14.8M | $29.9M | $102.5M | $2.3M | 10-K 2026-03-27 |
| Q3 2024 2024-09-30 | $214K | -$13.7M | -$16.3M | $40.4M | $104.4M | $2.3M | 10-Q 2025-11-12 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-03-11 |
| Latest annual report | 10-K | 2026-03-27 |
| Latest quarterly / interim | 10-Q | 2026-08-13 |
| Latest current report | 8-K | 2026-10-30 |
| Latest proxy | DEF 14A | 2025-11-12 |
Source: SEC EDGAR submissions feed, 672 recent filings. All filings on EDGAR.
The full dossier has every filing, quarterly and annual financials, the health record and a price chart.
Open the full dossier